LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Illumina Inc

Closed

SectorHealthcare

83.64 3.28

Overview

Share price change

24h

Current

Min

80

Max

84

Key metrics

By Trading Economics

Income

-56M

131M

Sales

-63M

1B

EPS

0.97

Profit margin

12.584

Employees

8,970

EBITDA

55M

284M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+42.53% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-3.4B

13B

Previous open

80.36

Previous close

83.64

News Sentiment

By Acuity

13%

87%

12 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Illumina Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 mar 2025, 09:18 UTC

Hot Stocks

Stocks to Watch Tuesday: Tesla, Oracle, Delta, Nvidia -- WSJ

10 mar 2025, 21:07 UTC

Top News

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

10 mar 2025, 20:01 UTC

Top News

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

4 mar 2025, 10:56 UTC

Hot Stocks

Stocks to Watch Tuesday: Illumina, Nvidia, Stellantis -- WSJ

Peer Comparison

Price change

Illumina Inc Forecast

Price Target

By TipRanks

42.53% upside

12 Months Forecast

Average 111.47 USD  42.53%

High 190 USD

Low 75 USD

Based on 20 Wall Street analysts offering 12 month price targets forIllumina Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

9

Buy

9

Hold

2

Sell

Technical Score

By Trading Central

77.61 / N/ASupport & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

12 / 382 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.